Relationship between the Prenatal Diagnosis of Placenta Acreta Spectrum and Lower Use of Blood Components

Relação entre o diagnóstico prenatal de espectro da placenta acreta e menor uso de hemoderivados

Néstor Pavón-Gómez1,2 Rita López1,2 Luis Altamirano2 Suhey Brahvo Cabrera1 Gusmara Porras Rosales1 Sergio Chamorro1,2 Karen González1 Amparo Morales1 Juliana Maya3 Stiven Sinisterra4 Albaro José Nieto-Calvache2,5

1Hospital Bertha Calderón Roque, Managua, Nicaragua 2Latin American Group for the Study of Placenta Accreta Spectrum, Cali, Colombia 3Programa de Medicina, Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia 4Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia 5Clínica de Espectro de Acretismo Placentario, Fundación Valle del Lili, Cali, Colombia

Address for correspondence Néstor Pavón-Gómez, Hospital Bertha Calderón Roque, Managua, Nicaragua (e-mail: nestorjaviermd@yahoo.com).

Rev Bras Ginecol Obstet 2022;44(12):1090–1093.

Abstract

Objective To describe the clinical results of patients admitted and managed as cases of placenta accreta spectrum (PAS) at a Central American public hospital and the influence of the prenatal diagnosis on the condition.

Materials and Methods A retrospective analysis of PAS patients treated at Hospital Bertha Calderón Roque, in Managua, Nicaragua, between June 2017 and September 2021. The diagnostic criteria used were those of the International Federation of Gynecology and Obstetrics (Fédération Internationale de Gynécologie et d’Obstétrique, FIGO, in French). The population was divided into patients with a prenatal ultrasonographic diagnosis of PAS (group 1) and those whose the diagnosis of PAS was established at the time of the caesarean section (group 2).

Results: During the search, we found 103 cases with a histological and/or clinical diagnosis of PAS; groups 1 and 2 were composed of 51 and 52 patients respectively. Regarding the clinical results of both groups, the patients in group 1 presented a lower frequency of transfusions (56.9% versus 96.1% in group 2), use of a lower number of red blood cell units (RBCUs) among those undergoing transfusions (median: 1; interquartile range: [IQR]: 0–4 versus median: 3; [IQR]: 2–4 in group 2), and lower frequency of 4 or more RBCU transfusions (29.4% versus 46.1% in group 2). Group 1 also exhibited a non-significant trend toward a lower volume of blood loss (1,000 mL [IQR]: 750–

DOI https://doi.org/10.1055/s-0042-1758712. ISSN 0100-7203.

© 2022, Federação Brasileira de Ginecologia e Obstetrícia. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Introduction

Placenta accreta spectrum (PAS) is a condition associated to massive hemorrhage and polytransfusion, and patients should be cared for by interdisciplinary groups in experienced centers. However, the participation of these expert groups relies on a prenatal diagnosis that enables the patient to be guided towards this type of care. The frequency of cases of PAS not diagnosed before laparotomy is variable, but it can be as high as 50%. In Nicaragua, among the factors that contribute to the low rate of prenatal diagnoses are the difficulties in training to identify PAS, the absence of centers with a high influx of patients, and the lack of feedback between the centers that carry out the diagnosis and those who deliver treatment. The present work describes the clinical results of the PAS patients managed at a Central American public hospital and the importance of establishing a prenatal diagnosis.

Materials and Methods

A retrospective analysis of medical records was carried out in search for patients with PAS treated at Hospital Bertha Calderón Roque, in Managua, Nicaragua, between June 2017 and December 2021. The diagnostic criteria used was those of the International Federation of Gynecology and Obstetrics (Fédération Internationale de Gynécologie et d’Obstétrique, FIGO, in French). The population was divided into patients with a prenatal PAS diagnosis by ultrasound submitted to surgery for that reason (group 1) and patients in whom PAS was only detected at the time of the caesarean section (group 2). During this period, the management protocol was standard, with no variations. All patients with a diagnosis of PAS underwent cesarean section at 35 weeks, with a plan for total hysterectomy after extraction of the fetus through the uterine fundus. Specific vascular control strategies nor ureteral catheters were used. All patients included had placenta previa and underwent cesarean hysterectomy, same surgical technique was applied. The present retrospective study was approved by the Institutional Review Board/Ethics Committee for Biomedical Research (under no. 1494). A descriptive statistical analysis was carried out; The continuous variables were expressed as median and interquartile range (IQR) values, and they were analyzed using the Mann-Whitney U test. The qualitative variables were expressed as absolute and relative frequencies, and the comparison between them was made using the Chi-squared test or the Fisher exact test according to the case. Statistical significance was defined as \( p < 0.05 \). The analyses were performed using the STATA (StataCorp LLC, College Station, TX, United States) software, version 14.

Results

During the study period, 114 women with a histological and/or clinical diagnosis of PAS were found: 51 patients had a prenatal PAS diagnosis by ultrasound (group 1), and 63 were only diagnosed when they underwent laparotomy (group 2).

Chart 1 summarizes the clinical results of both groups, showing a lower frequency of transfusions in group 1 (56.9% versus 87.3% in group 2), as well as the use of a lower number of red blood cell units (RBCUs) in said transfused patients (median: 1; IQR: 0–4 versus median: 3; IQR: 2–4 in group 2). The frequency of 4 or more RBCU transfusions was also lower in group 1 (29.4% versus 44.4% in group 2). Group 2 underwent surgery at a higher gestational age (mean: 38 weeks; IQR: 35–39 weeks versus median: 34 weeks; IQR: 32–36 weeks in group 1), with a lower rate of participation of interdisciplinary groups (62.4% versus 90.2% in group 1) and of elective surgeries than group 1 (22.2% in group 2 versus 78.4% in group 1). Group 1 also exhibited a non-significant trend toward a lower volume of blood loss (median: 1,000 mL; IQR: 750–2,000 mL versus median: 1,500 mL; IQR: 1,300–2,200 mL in group 2), lower requirement of pelvic packing with compresses to control bleeding (1.9% versus 7.9% in group 2), surgical reinterventions (11.8% versus 17.5% in group 2), and surgical site infection (1.9% versus 4.8% in group 2) than group 2. In a high percentage of patients (35; 30.9%), the histological diagnosis was not available because the tissue had not been not processed by the pathology department.

Discussion

Less than half of our cases (44.7%) had a prenatal PAS diagnosis (group 1). Patients in group 1 had a lower frequency of transfusions and those among them who received blood components required a lower number of RBCUs. Although some expert groups have reported excellent performance of the PAS ultrasonographic diagnosis, even in some high-income countries the frequency of false positives is close to that observed in the Nicaraguan population, with a rate of intraoperative diagnosis close to 50%. There are multiple factors that explain a poor performance in establishing a PAS prenatal diagnosis in our population. Although all the patients included in the present study underwent prenatal pelvic packing 2,000 mL versus 1,500 mL [IQR]: 1,200–1,800 mL in group 2), and lower requirement of pelvic packing (1.9% versus 7.7% in group 2).
follow-up visits and periodic ultrasonographic scans, Nicaragua has not established protocols to diagnose PAS. Additionally, there are few maternal–fetal medicine specialists or prenatal ultrasonography experts. Finally, there is no chair in the diagnosis and treatment of PAS in the obstetrics training programs in our country. It is important to point out these difficulties as the first step towards improving the prenatal identification of PAS. It is likely that the knowledge of a prenatal PAS diagnosis in group 1 facilitated the scheduling of the surgical procedure, which was elective in 78.4% of these patients, unlike group 2, in which it was elective in 22.2% of the cases, and at a higher gestational age (median: 34 weeks; IQR: 32–36 weeks in group 1 versus median: 38 weeks; IQR: 35–39 weeks in group 2).

One of the advantages of knowing the PAS diagnosis is the possibility of “scheduling” the participation of the interdisciplinary groups during surgery.10–12 Our hospital does not have an interdisciplinary group dedicated to the treatment of PAS (a “PAS team”); however, patients from group 1 were treated by the more experienced surgeons available, which included the urologist and the teneral surgeon on duty that day. This was possible in 90.2% of the cases in group 1, and only in 62.4% of the cases in group 2. In the event that the diagnosis of PAS was a “surprise” during the laparotomy, calling the surgeon and the urologist on duty was left at the discretion of the obstetricians in charge of the surgery. Other authors5 have pointed out the importance of prenatal diagnosis and its relationship with lower levels of blood loss and lower use of transfusions, and they also coincide in documenting important differences in the management of patients with and without a prenatal diagnosis.

Our hospital is a reference center for the most critical obstetric conditions in the country, but like many other hospitals with similar characteristics, it does not have a PAS team.13 Our flaws in the prenatal diagnosis (intraoperative finding of PAS in 55.2% of our cases) and histological analysis (absence of analysis by a pathologist in 35 cases) result in an opportunity to improve the quality of care in our center.

The present study has limitations. Its retrospective design makes it more susceptible to bias. The absence of histological confirmation in 30.7% of the cases enabled the inclusion of non-PAS cases; however, patients whose medical record described macroscopic findings compatible with the FIGO definition were included. The present is the first evaluation of the clinical results of PAS management in Nicaragua, and one of the few that have been carried out in Central America.

The results shed light on the need to design improvement plans at the national level, with the need for multicenter prospective studies to confirm our observations and evaluate the effect of interventions already implemented, such as the creation of a PAS team that is provided with specific training in the management of this disease, the proposal of including PAS screening in routine prenatal care appointments for women with risk factors, and the project of including a section about PAS in the national guidelines for the treatment of postpartum hemorrhage.

---

**Chart 1** Comparison of the clinical results of PAS patients with and without a prenatal diagnosis

|                          | Group 1 (n = 51): WITH prenatal diagnosis | Group 2 (n = 63): WITHOUT prenatal diagnosis | p-value |
|--------------------------|------------------------------------------|---------------------------------------------|---------|
| Gestational age at surgery (in weeks)* | 34 (32-36)                               | 38 (35-39)                                 | 0.003   |
| Surgical time (in minutes)* | 103 (82-145)                              | 94 (74-129)                                | 0.235   |
| Interdisciplinary group participation: n (%) | 46 (90.2)                                 | 33 (62.4)                                  | 0.003   |
| Elective surgery: n (%)     | 40 (78.4)                                 | 14 (22.2)                                  | 0.002   |
| Bleeding volume (mL)*      | 1000 (750-2000)                           | 1500 (1300-2200)                           | 0.347   |
| Transfusions: n (%)        | 29 (56.9)                                 | 55 (87.3)                                  | 0.005   |
| Number of RBCUs transfused | 1 (0-4)                                   | 3 (2-4)                                    | 0.027   |
| 4 or more RBCUs: n (%)     | 15 (29.4)                                 | 28 (44.4)                                  | 0.039   |
| Bladder injury: n (%)      | 7 (13.7)                                  | 9 (14.2)                                   | 0.923   |
| Ureteral injury: n (%)     | 2 (3.9)                                   | 0                                          | –       |
| Urinary fistula: n (%)     | 0                                         | 1 (1.6)                                    | –       |
| Pelvic packing with compresses: n (%) | 1 (1.9)                                  | 5 (7.9)                                    | 0.380   |
| Reintervention: n (%)      | 6 (11.8)                                  | 11 (17.5)                                  | 0.996   |
| Wound infection: n (%)     | 1 (1.9)                                   | 3 (4.8)                                    | 0.666   |
| Death: n (%)               | 1 (1.9)                                   | 1 (1.6)                                    | 0.104   |
| Histological analysis: n (%) |                                        |                                            |         |
| Placenta acreta            | 24 (47.1)                                 | 34 (53.9)                                  | 0.890   |
| Placenta increta           | 11 (21.6)                                 | 6 (9.5)                                    |         |
| Placenta percreta          | 2 (3.9)                                   | 2 (3.2)                                    |         |
| No histological study      | 14 (27.4)                                 | 21 (33.3)                                  |         |

Abbreviations: PAS, placenta accreta spectrum; RBCU, red blood cells unit.
Note: *Median (interquartile range).

---

1092 Prenatal Diagnosis of Placenta Acreta Spectrum and Lower Use of Blood Components Pavón-Gomez et al.
Conclusion

The presence of a prenatal diagnosis of PAS is related to a lower frequency of RBCU transfusions. We observed a high frequency of failures within the prenatal PAS diagnostic steps. It is a priority to improve the prenatal detection of this disease.

Contributions
All authors made substantial contributions to the conception and design, data collection or analysis, and interpretation of data, writing of the article or critical review of the intellectual content, and final approval of the version to be published.

Conflict of Interests
The authors have no conflict of interests to declare.

References
1. DeSimone RA, Leung WK, Schwartz J. Transfusion medicine in a multidisciplinary approach to morbidity adherent placenta: preparing for and preventing the worst. Transfus Med Rev. 2018;32(04):244–248. DOI: 10.1016/j.tmr.2018.05.007
2. Silver RM, Fox KA, Barton JR, et al. Center of excellence for placenta accreta. Am J Obstet Gynecol. 2015;212(05):561–568. DOI: 10.1016/j.ajog.2014.11.018
3. Collins SL, Alemdar B, van Beekhuizen HJ, et al; International Society for Abnormally Invasive Placenta (IS-AIP) Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol. 2019;220(06):511–526. DOI: 10.1016/j.ajog.2019.02.054
4. Allen L, Jauniaux E, Hobson S, Papillon-Smith J, Belfort MA FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Nonconservative surgical management. Int J Gynaecol Obstet. 2018;140(03):281–290. DOI: 10.1002/ijgo.12409
5. Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG. 2014;121(01):62–70, discussion 70–71. DOI: 10.1111/1471-0528.12405
6. Silveira C, Kirby A, Melov SJ, Nayyar R. Placenta accreta spectrum: We can do better. Aust N Z J Obstet Gynaecol. 2022;62(03):376–382. DOI: 10.1111/ajo.13471
7. Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins SF FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019;146(01):20–24. DOI: 10.1002/ijgo.12761
8. Cali G, Forlani F, Dimor-Trisch I, et al. Diagnostic accuracy of ultrasound in detecting the depth of invasion in women at risk of abnormally invasive placenta: A prospective longitudinal study. Acta Obstet Gynecol Scand. 2018;97(10):1219–1227. DOI: 10.1111/aogs.13389
9. Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;217(01):27–36. DOI: 10.1016/j.ajog.2017.02.050
10. Chantraine F, Braun T, Gonser M, Henrich W, Tutschek B. Prenatal diagnosis of abnormally invasive placenta reduces maternal peripartum hemorrhage and morbidity. Acta Obstet Gynecol Scand. 2013;92(04):439–444. DOI: 10.1111/aogs.12081
11. Weiniger CF, Einav S, Deutsch L, Ginosar Y, Ezra Y, Eid L. Outcomes of prospectively-collected consecutive cases of antenatal-suspected placenta accreta. Int J Obstet Anesth. 2013;23(04):273–279. DOI: 10.1016/j.ijoa.2013.04.014
12. Hall T, Wax JR, Lucas FL, Cartin A, Jones M, Pinette MG. Prenatal sonographic diagnosis of placenta accreta-impact on maternal and neonatal outcomes. J Clin Ultrasound. 2014;42(08):449–455. DOI: 10.1002/jcu.22186
13. Nieto-Calvache AJ, Palacios-Jaraquemada JM, Hidalgo A, et al. Management practices for placenta accreta spectrum patients: a Latin American hospital survey. J Matern Fetal Neonatal Med. 2021;[ahead of print]. DOI: 10.1080/14767058.2021.1906858